Korea Rising: Don't Be Late to Asia's Next Innovation Hub
June 23, 2026
23BC
Type: Breakout Session
Focus Area:
Emerging Opportunities in Global Markets
Many Western biopharma leaders look back and wish they had engaged earlier with the China story. A similar inflection point is now unfolding in Korea, and the time to engage early is now. South Korea leads ex-China Asia in dealmaking, with first-in-class assets outweighing non-FIC programs across recent deal flow. Early movers like ABL Bio, Alteogen, and LigaChem Biosciences are finding global partners, translation-ready academic programs are generating licensing and Newco opportunities, and multinationals like Roche and Lilly are placing bets on Korea becoming the next Asia innovation hub. Korea also offers Western biotechs world-class CDMOs and clinical trial centers to help de-risk assets, fast. In this spotlight session, BioCentury and BIO bring together industry leaders to discuss which strengths differentiate the Korea ecosystem and how best to engage partners there now.
Moderator
.png)
Speakers
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}